Scientists at the University of Cambridge and DIOSynVax have tested an AI-designed universal coronavirus vaccine in a Phase 1 trial involving 39 healthy volunteers, with results published in the Journ…
The University of Cambridge and biotech firm DIOSynVax Ltd announced on June 5 that a Phase I clinical trial of 39 healthy volunteers showed their AI-designed vaccine is safe, well-tolerated, and trig…
A University of Cambridge team and spin-out DIOSynVax reported that a Phase 1 trial of an AI-designed "super-antigen" vaccine was safe and immunogenic in 39 healthy volunteers. The vaccine, whose acti…
The University of Cambridge and spinout company DIOSynVax have successfully tested the first AI-designed universal coronavirus vaccine in humans, finding it safe and well-tolerated in a 39-volunteer t…
The University of Cambridge successfully tested a vaccine with an antigen designed entirely by artificial intelligence, marking the first time a computer-designed active component has been used in hum…